ENLV vs. NNVC, JAN, BIOR, ACST, UBX, ONCT, DRRX, LPCN, ITRM, and FBRX
Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include NanoViricides (NNVC), JanOne (JAN), Biora Therapeutics (BIOR), Acasti Pharma (ACST), Unity Biotechnology (UBX), Oncternal Therapeutics (ONCT), DURECT (DRRX), Lipocine (LPCN), Iterum Therapeutics (ITRM), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical preparations" industry.
Enlivex Therapeutics (NASDAQ:ENLV) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, community ranking, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.
NanoViricides is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.
Enlivex Therapeutics received 49 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
Enlivex Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 400.00%. Given Enlivex Therapeutics' higher probable upside, equities analysts plainly believe Enlivex Therapeutics is more favorable than NanoViricides.
1.0% of Enlivex Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, NanoViricides had 4 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 5 mentions for NanoViricides and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 1.18 beat NanoViricides' score of 0.47 indicating that Enlivex Therapeutics is being referred to more favorably in the media.
NanoViricides' return on equity of -70.80% beat Enlivex Therapeutics' return on equity.
Enlivex Therapeutics has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Summary
Enlivex Therapeutics beats NanoViricides on 9 of the 14 factors compared between the two stocks.
Get Enlivex Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enlivex Therapeutics Competitors List
Related Companies and Tools
